We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.67%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$405M
AUM Growth
+$48.5M
(+14%)
Cap. Flow
+$65.2M
Cap. Flow
% of AUM
16.1%
Top 10 Holdings %
Top 10 Hldgs %
49.16%
Holding
86
New
12
Increased
27
Reduced
11
Closed
19
Top Buys
| 1 |
Nuvalent
NUVL
|
+$21.9M |
| 2 |
Erasca
ERAS
|
+$16.4M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.9M |
| 4 |
UroGen Pharma
URGN
|
+$8.44M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$7.74M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
+$7.96M |
| 2 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$7.89M |
| 3 |
Solid Biosciences
SLDB
|
+$7.63M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$5.98M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$5.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $36.9M | 9.11% |
623,628
+57,341
| +10% | +$2.78M |
|
|
2
Nuvalent
NUVL
$9.81B
| $35.3M | 8.72% |
465,710
+307,960
| +195% | +$21.9M |
|
|
RNAM
3
DELISTED
Avidity Biosciences
RNAM
| $21.1M | 5.22% |
517,734
+28,431
| +6% | +$816K |
|
|
4
UroGen Pharma
URGN
$1.88B
| $18.5M | 4.57% |
1,102,000
+593,413
| +117% | +$8.44M |
|
|
5
Erasca
ERAS
$6.23B
| $18.4M | 4.55% |
7,816,926
+7,593,081
| +3,392% | +$16.4M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $16.6M | 4.09% |
486,306
+2,334
| +0.5% | +$69.1K |
|
|
AKRO
7
DELISTED
Akero Therapeutics
AKRO
| $14.7M | 3.62% |
625,087
+225,138
| +56% | +$4.81M |
|
8
Celldex Therapeutics
CLDX
$3B
| $13.9M | 3.43% |
374,910
+75,594
| +25% | +$2.85M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13.2M | 3.25% |
192,345
+157,538
| +453% | +$10.9M |
|
|
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $10.5M | 2.6% |
3,607,999
+11,523
| +0.3% | +$31.5K |
|
11
Cogent Biosciences
COGT
$6.57B
| $10.2M | 2.51% |
1,206,214
+169,547
| +16% | +$1.29M |
|
12
Insmed
INSM
$23.5B
| $9.38M | 2.32% |
140,000
+26,384
| +23% | +$1.02M |
|
13
Alnylam Pharmaceuticals
ALNY
$37.5B
| $8.75M | 2.16% |
+36,000
| New | +$5.68M |
|
14
Elutia
ELUT
$40.7M
| $7.95M | 1.96% |
1,603,580
+1,525,000
| +1,941% | +$4.96M |
|
15
Corbus Pharmaceuticals
CRBP
$165M
| $7.81M | 1.93% |
172,492
+140,512
| +439% | +$5.91M |
|
16
Oric Pharmaceuticals
ORIC
$1.11B
| $7.61M | 1.88% |
1,075,812
-37,195
| -3% | -$333K |
|
|
17
Syndax Pharmaceuticals
SNDX
$2.11B
| $7.6M | 1.88% |
+370,000
| New | +$7.74M |
|
18
Rhythm Pharmaceuticals
RYTM
$7.42B
| $7.58M | 1.87% |
184,662
+886
| +0.5% | +$35.4K |
|
19
C4 Therapeutics
CCCC
$417M
| $6.67M | 1.65% |
1,442,841
+6,910
| +0.5% | +$41.2K |
|
20
Sarepta Therapeutics
SRPT
$1.89B
| $6.64M | 1.64% |
+42,000
| New | +$5.4M |
|
|
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
| $6.61M | 1.63% |
560,883
-300
| -0.1% | -$3.5K |
|
22
Veracyte
VCYT
$4.67B
| $6.12M | 1.51% |
282,248
+1,475
| +0.5% | +$31K |
|
|
ABVX
23
Abivax
ABVX
$11.9B
| $6.03M | 1.49% |
455,800
+380,800
| +508% | +$5.45M |
|
24
Olema Pharmaceuticals
OLMA
$1.04B
| $5.92M | 1.46% |
546,863
+31,546
| +6% | +$342K |
|
25
ADC Therapeutics
ADCT
$158M
| $5.59M | 1.38% |
1,768,770
+1,267,548
| +253% | +$5.04M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA